Ruthenium-based chemotherapeutics: are they ready for prime time? Emmanuel S. AntonarakisAshkan Emadi Mini Review 06 March 2010 Pages: 1 - 9
N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU Xiaofan ZhangJulia Li ZhongXianjun Qu Original Article Open access 16 September 2009 Pages: 11 - 19
Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro Hui-Jun ZhouJia-Li ZhangXiao-E Lou Original Article 16 September 2009 Pages: 21 - 29
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer Jin Young KimYoung Rok DoHong Suk Song Original Article 18 September 2009 Pages: 31 - 36
Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer Yunfei CaoLidan LiuFeng Gao Original Article 17 September 2009 Pages: 37 - 42
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models Alberto GabizonDina TzemachSamuel Zalipsky Original Article 25 September 2009 Pages: 43 - 52
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin M. RansonH. ShawI. Judson Original Article 03 December 2009 Pages: 53 - 58
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer Kaisa Leea SunelaSanna KoskinenPirkko-Liisa Kellokumpu-Lehtinen Original Article 22 September 2009 Pages: 59 - 67
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells Jose PradosConsolación MelguizoAntonia Aránega Original Article 22 September 2009 Pages: 69 - 78
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma Andréia Hanada OtakeAna Lucia MattarRoger Chammas Original Article 22 September 2009 Pages: 79 - 87
Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer Norikazu MasudaTakahiro NakayamaJunichi Sakamoto Original Article 19 September 2009 Pages: 89 - 94
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients Kimie SaiYoshiro SaitoHironobu Minami Original Article 22 September 2009 Pages: 95 - 105
Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer Masafumi YamaguchiSadanori TakeoHironori Matsuzawa Original Article 07 October 2009 Pages: 107 - 112
Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge Elodie VauléonHabiba MesbahPierre Kerbrat Original Article 27 September 2009 Pages: 113 - 120
Effects of extracellular purines on cytotoxicity of methotrexate Li ChongGuoyi MaMartin H. N. Tattersall Original Article 27 September 2009 Pages: 121 - 127
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors Metin KurtogluKatherine PhilipsTheodore J. Lampidis Original Article 25 September 2009 Pages: 129 - 140
Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells Jingjing GuoSudhakar ChintharlapalliStephen Safe Original Article 13 October 2009 Pages: 141 - 150
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors Bhuvaneswari RamaswamyTanios Bekaii-SaabCharles L. Shapiro Original Article 23 September 2009 Pages: 151 - 158
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study Shabnam N. SaniKatherine HenryTimothy J. Maher Original Article 09 October 2009 Pages: 159 - 169
Sensitivity of breast cancer cell lines to recombinant thiaminase I Shuqian LiuNoel R. MonksJeffrey A. Moscow Original Article 15 October 2009 Pages: 171 - 179
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer Dana RathkopfBryan Y. WongHoward I. Scher Clinical Trial Report 09 March 2010 Pages: 181 - 189
A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie Volker KaecheleMarkus MoehlerThomas Seufferlein Clinical Trial Report 31 March 2010 Pages: 191 - 195
“Metronomic” chemotherapy in advanced soft tissue sarcomas Antoine ItalianoMaud ToulmondeBinh Bui Short Communication 25 February 2010 Pages: 197 - 202
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer Martin PölcherMeike EckhardtChristian Rudlowski Short Communication 05 March 2010 Pages: 203 - 207
